News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News LifeArc spends Keytruda cash on R&D ignored by pharma Formerly known as MRC Technology, charity to spend Keytruda royalties on R&D considered too risky by big pharma
Views & Analysis Immunotherapies in oncology: the future of cancer treatment ... Partnerships, co-marketing and the positioning of drugs are shaping the competitive landscape in oncology.
News Scotland decision helps Opdivo in UK market access picture The last 18 months has seen groundbreaking cancer immunotherapies, led by BMS’s Opdivo and Merck Sharp & Dohme’s Keytruda hit the UK market, with both rapidly adding multiple indication
News Senate could back Trump health law by 4th July, despite warn... Reforms could take away health insurance from 23 million, and deny insurance to those with pre-existing conditions, such as diabetes
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
